Drug intelligence / Profile preview

CK-089

Development stage: Unknown
Lead developer: Cytokinetics
Modality: Small Molecules
Administration: Oral

Overview

CK-089, also known as CK-4015089, is a novel, selective, oral, small molecule fast skeletal muscle troponin activator (FSTA) developed by Cytokinetics. It is designed to selectively activate the fast skeletal muscle troponin complex by increasing its affinity for calcium. This mechanism aims to improve muscle force and function, making it a potential therapeutic candidate for a specific type of muscular dystrophy and other conditions characterized by impaired muscle function, weakness, atrophy, and fatigue.

Targets

TNNC2 (Troponin C type 2)

Beyond the preview

Go deeper on CK-089.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CK-089.

Explore the full profile